



## EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司\*

*(Incorporated in Bermuda with limited liability)*

(Stock Code: 00858)

### UNUSUAL PRICE AND VOLUME MOVEMENT

This statement is made at the request of The Stock Exchange of Hong Kong Limited.

We have noted the recent increases in the price and trading volume of the shares of Extrawell Pharmaceutical Holdings Limited (the “Company”).

Save as disclosed in the Company’s announcement dated 1 August 2007 regarding the acquisition of minority interests in Smart Ascent Limited, the indirect non-wholly owned subsidiary of the Company (the “Acquisition”) and circular dated 22 August 2007 regarding the Acquisition, we are not aware of any reasons for such increases in price and in trading volume.

We also confirm that there are no negotiations or agreements relating to intended acquisitions or realisations which are discloseable under rule 13.23, neither is the board of directors (the “Board”) aware of any matter discloseable under the general obligation imposed by rule 13.09, which is or may be of a price-sensitive nature.

Made by the order of the Board, the directors of which individually and jointly accept responsibility for the accuracy of this statement.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Elsie Wong**  
*Company Secretary*

Hong Kong, 24 August 2007

*As at the date of this announcement, the Board of the Company comprises Dr. Mao Yu Min, Mr. Ho Chin Hou, Mr. Ho Yu Ling, Mr. Li Qiang and Dr. Xie Yi as executive directors; and Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song as independent non-executive directors.*

\* *For identification purposes only*